◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksB › BONS

Bonus BioGroup Ltd. (BONS) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-09-19

Bonus BioGroup Ltd. (BONS) operates in the Biotechnology industry and is headquartered in Haifa, Israel with about 42 employees. Its market capitalization is roughly ₪227 million. In the fiscal year ended 2025-12-31, BONS reported ₪0M in revenue and (₪24M) in net income.

Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy.

Interactive charts & full statements →

BONS Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue₪0M₪0M₪0M₪0M
Gross Profit(₪2M)(₪3M)(₪3M)(₪4M)
Operating Income (EBIT)(₪24M)(₪28M)(₪30M)(₪37M)
Net Income(₪24M)(₪28M)(₪28M)(₪39M)

ILS; ₪M / ₪B as marked. Newest period first. Source: company filings via the Israel Securities Authority’s Magna disclosure system.

BONS Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2024-12-31
Total Revenue₪0M
Operating Income (EBIT)(₪6M)
Net Income(₪6M)

ILS; ₪M / ₪B as marked. Newest period first. Source: company filings via the Israel Securities Authority’s Magna disclosure system.

BONS Free Cash Flow History

BONS Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets₪15M₪23M₪45M₪75M
Total Liabilities₪21M₪16M₪16M₪18M

ILS; ₪M / ₪B as marked. Newest period first. Source: company filings via the Israel Securities Authority’s Magna disclosure system.

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BONS viewer.

Other Companies in Biotechnology

This page in other languages: עברית

← BONLONAll “B” companiesBOOM →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.